Market OpportunityNotalgia paresthetica affects approximately 650,000 patients in the US, presenting a projected market opportunity of over $300 million with no current FDA-approved therapies.
Stock ValuationThere is a highly positive risk-reward with Cara currently trading at around 0.5 times cash, making it an attractive investment ahead of the anticipated trial results.
Trial Data AnnouncementCARA plans to announce data from the Part A dose-finding portion of the Ph2/3 KOURAGE-1 trial in notalgia paresthetica, a condition with no FDA-approved drugs, which could significantly impact the stock.